Showing 3741-3750 of 8824 results for "".
- IEC Session Highlights AA/AD Connectionhttps://practicaldermatology.com/news/IEC-Session-Highlights-AA-AD-Connection/2471516/The International Eczema Council (IEC) meeting in advance of the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, was a crossover event. The IEC partnered with both the National Eczema Association (NEA) and National Alopecia Areata Foundation (NAAF) to present
- Analysis: Biosimilars Show Comparable Effectiveness to Humira in Psoriasishttps://practicaldermatology.com/news/analysis-biosimilars-show-comparable-effectiveness-to-humira-in-psoriasis/2471496/Adalimumab biosimilars Amjevita and Imraldi showed similar effectiveness to Humira for the treatment of psoriasis in both new users and patients switching from Humira, according to an analysis of the British Association of Dermatologists Biologics and Immunomodulato
- Phase 1 Trial Shows Safety and Dosing Potential for Combo IL-13 Therapy for ADhttps://practicaldermatology.com/news/phase-1-trial-shows-safety-and-dosing-potential-for-combo-il-13-therapy-for-ad/2471401/Apogee Therapeutics has reported positive interim results from a Phase 1 trial evaluating APG990, a subcutaneous, extended half-life monoclonal antibody targeting OX40L, for inflammatory and immunological conditions such as atopic dermatitis (AD), according to a pre
- Study: AI Model Improves Hair Growth, Texturehttps://practicaldermatology.com/news/ai-model-improves-hair-growth-texture/2471394/An artificial intelligence (AI)-driven platform for customizing hair loss treatments significantly improved hair growth, scalp health, and hair texture in a 24-week study involving women with self-reported hair thinning. The st
- Sanofi to Present Data on Dupilumab for BP, AD, CSU, PN, Plus Amlitelimabhttps://practicaldermatology.com/news/Sanofi-Present-Data-Dupilumab-BP-AD-CSU-PN-Plus-Amlitelimab/2471384/Sanofi will present 26 abstracts, including one late-breaking and five additional oral presentations, across approved and investigational medicines at the American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, from March 7-11. Presentations in partnership with Regeneron
- Analysis: Nicotinamide Not Linked to Elevated MACE Riskhttps://practicaldermatology.com/news/study-nicotinamide-not-linked-to-mace-risk/2471380/Results from a new retrospective cohort study suggest nicotinamide exposure was not associated with an increased risk of major adverse cardiovascular events (MACE). The analysis included data from 13,108 patients in the Vanderb
- FDA Accepts sNDA for Roflumilast Cream for AD Patients Ages 2-5https://practicaldermatology.com/news/FDA-Accepts-sNDA-Roflumilast-Cream-AD-Patients-Ages-2-5/2471351/The US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for ZORYVE (roflumilast) cream 0.05%, for the topical treatment of mild to moderate atopic dermatitis (AD) in children 2 to 5 years old, Arcutis Biotherapeutics, Inc. announced. The FDA has se
- New INTEGUMENT-PED Results Support Roflumilast Cream for Pediatric ADhttps://practicaldermatology.com/news/phase-3-trial-supports-roflumilast-cream-for-young-children-with-ad/2471293/Arcutis Biotherapeutics announced today that the INTEGUMENT-PED Phase 3 trial had met its primary endpoint, according to a release from the manufacturer. Researchers on the study evaluated the efficacy and safety of roflumilast cr
- Analysis: Sustained Eczema and Psoriasis Remission Achieved with Dupilumabhttps://practicaldermatology.com/news/analysis-sustained-eczema-and-psoriasis-remission-achieved-with-dupilumab/2471286/A new study highlights the potential of dupilumab to deliver sustained remission in children with moderate-to-severe atopic dermatitis (AD). The findings, presented as a poster at the 2025 Masterclasses in Dermatology conference
- Care Urged for Adult-Onset AD Diagnoseshttps://practicaldermatology.com/news/Care-Urged-Adult-Onset-AD-Diagnoses/2471216/As revolutionary as the latest approved therapeutics for atopic dermatitis have been, Daniela Kroshinsky, MD, MPH, cautioned that dermatologists must be vigilant and consider biopsies for atypical or nonresponsive cases before starting dupilumab or a JAK inhibitor. Speaking at the Winter C